株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

中国のリツキシマブ市場の分析

Investigation Report on Chinese Rituximab Market, 2018-2022

発行 China Research and Intelligence 商品コード 296864
出版日 ページ情報 英文 30 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.06円で換算しております。
Back to Top
中国のリツキシマブ市場の分析 Investigation Report on Chinese Rituximab Market, 2018-2022
出版日: 2018年07月17日 ページ情報: 英文 30 Pages
概要

リツキシマブ(Roche社「マブセラ」、Genentech社「リツキサン」)は、腫瘍の治療薬として1997年に承認された、CD20抗原に対するキメラ型モノクローナル抗体です。B細胞リンパ腫の治療に非常に有効で、良好な耐性を示しています。世界のリツキシマブ市場の売上高は、2010年が50億3,400万米ドル、2011年が61億4,000万米ドル、2012年が71億4,300万米ドルと、順調に推移し、2014には80億米ドルを超えました。

当レポートでは、中国におけるリツキシマブ市場について調査分析し、主要メーカーの市場シェア、病院市場での販売価格、病院市場での市場シェア(剤形別)、自己免疫疾患の発生率、ジェネリック医薬品の製造スケジュール、市場の見通しなどをお届けいたします。

第1章 リツキシマブの関連概念

  • 適応
  • 世界市場の販売状況

第2章 中国におけるリツキシマブの市場概要

  • 特許の状況
  • 主要メーカー
  • 市場規模

第3章 中国におけるリツキシマブの売上高の分析

  • 総売上高
  • 売上高:地域別

第4章 中国におけるリツキシマブの主要メーカーの市場シェアの分析

  • 市場シェア:売上高別
  • 市場シェア:販売量別

第5章 中国におけるリツキシマブ(剤形別)の市場規模の分析

  • 市場シェア:売上高・剤形別
  • 市場シェア:販売量・剤形別

第6章 中国の病院市場におけるリツキシマブの基準価格

  • Hoffmann-La Roche, Inc.
  • Roche Diagnostics
  • Shanghai Roche Pharmaceutical Co., Ltd.

第7章 中国におけるリツキシマブの主要メーカー

  • Hoffmann-La Roche, Inc.
  • Roche Diagnostics
  • Shanghai Roche Pharmaceutical Co., Ltd.

第8章 中国のリツキシマブ市場の見通し

  • 非ホジキンリンパ腫・自己免疫疾患の発生率の予測
  • リツキシマブの市場規模の予測
  • リツキシマブの競合パターンの予測

図表

目次
Product Code: 1807311

Description

Rituximab (Roche's trade name: Rituxan) is a human-mouse chimeric anti-CD20 monoclonal antibody that was approved for the treatment of tumors in 1997. With the deep understanding of B cells and their mechanisms of action, the therapeutic range of Rituximab has expanded from B-cell malignancies to autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, idiopathic thrombocytopenic purpura, etc.

The global sales of Rituximab have been very mature. In fiscal year 2017, Rituximab recorded a revenue of CHF 7.388 billion, a YOY increase of 1.21%. The drug was mostly used for tumor treatment. In fiscal year 2017, the sales value from tumor treatment reached CHF 5.832 billion, increasing by 0.15% YOY, and the sales value from the treatment of autoimmune diseases reached CHF 1.556 billion, increasing by 5.35% YOY. In China, Roche's Rituximab is mainly used to treat non-Hodgkin lymphoma.

As a major malignant lymphoma, non-Hodgkin lymphoma takes up a much larger proportion of malignant lymphoma than Hodgkin's disease in China. The incidence of non-Hodgkin's lymphoma has risen rapidly from 20 cases per 1 million people at the end of the 20th century to 70 cases per 1 million people today. Autoimmune diseases may affect organs such as the central nervous system, lungs, liver and kidneys, cause dysfunction or even failure of organs, and ultimately threaten life. Statistics show that there are about 30 to 40 million people suffering from autoimmune diseases in China, which leads to a growing demand for Rituximab. In 2017, the sales value of Rituximab exceeded CNY 1 billion in China.

According to CRI, by Jul. 2018, there has been no China-made Rituximab on the market, and the market is monopolized by the products of Roche and its subsidiary Genentech. Several domestic manufacturers have applied for approval to produce generic Rituximab. It is expected that generic Rituximab will be launched after 2020. There is still a large growth potential for the Chinese Rituximab market.

Topics Covered:

  • Development environment of Chinese Rituximab market
  • Sales of Rituximab in China
  • Prices of Rituximab in China
  • Progress of generic Rituximab in China
  • Prospects of Chinese Rituximab Market, 2018-2022

Table of Contents

Table of Contents

1 Basic Concepts of Rituximab

  • 1.1 Indications for Rituximab
  • 1.2 Development History of Rituximab in China
  • 1.3 Governmental Approval of Rituximab in China

2 Sales of Rituximab in China, 2013-2017

  • 2.1 Sales Value of Rituximab
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value in Parts of China
  • 2.2 Sales Volume of Rituximab
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume in Parts of China
  • 2.3 Sales of Rituximab by Dosage Form

3 Major Rituximab Manufacturers in China, 2013-2017

  • 3.1 Market Share of Major Rituximab Manufacturers in China
    • 3.1.1 Market Share by Sales Value
    • 3.1.2 Market Share by Sales Volume
  • 3.2 Roche
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of Roche's Rituximab in China
  • 3.3 Genentech
    • 3.3.1 Enterprise Profile
    • 3.3.2 Sales of Genentech's Rituximab in China

4 Prices of Rituximab in China, 2017-2018

  • 4.1 Average Prices of Rituximab in China
    • 4.1.1 National Average Price
    • 4.1.2 Average Price by Region
  • 4.2 Prices of Major Manufacturers' Rituximab in China
    • 4.2.1 Price of Roche's Rituximab in China
    • 4.2.2 Price of Genentech's Rituximab in China

5 Prospects of Chinese Valsartan Market, 2018-2022

  • 5.1 Factors Influencing Rituximab Development in China
    • 5.1.1 Driving Forces and Market Opportunities
    • 5.1.2 Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Competition Pattern

Selected Charts

  • Chart Rituximab Products Approved to Market in China by 2018
  • Chart Sales Value of Rituximab in China, 2013-2017
  • Chart Sales Value of Rituximab by Region in China, 2013-2017
  • Chart Market Share of Rituximab Manufacturers by Sales Value in China, 2013-2017
  • Chart Prices of Roche's Rituximab in Key Regions of China, 2017-2018
  • Chart Prices of Genentech's Rituximab in Key Regions of China, 2017-2018
  • Chart Forecast on Sales of Rituximab in China, 2018-2022
  • Chart Generic Rituximab in China
Back to Top